keyword
MENU ▼
Read by QxMD icon Read
search

Ustekinumab crohn's

keyword
https://www.readbyqxmd.com/read/27885650/anti-il-12-23p40-antibodies-for-induction-of-remission-in-crohn-s-disease
#1
REVIEW
John K MacDonald, Tran M Nguyen, Reena Khanna, Antje Timmer
BACKGROUND: Ustekinumab (CNTO 1275) and briakinumab (ABT-874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease. OBJECTIVES: The objectives of this review were to assess the efficacy and safety of anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. SEARCH METHODS: We searched the following databases from inception to 12 September 2016: PubMed, MEDLINE, EMBASE, and the Cochrane Library (CENTRAL)...
November 25, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27722763/ustekinumab-as-effective-treatment-for-refractory-amicrobial-pustulosis-of-the-folds-associated-with-crohn-s-disease
#2
Reem Al-Raddadi, Camille Frances, Philippe Moguelet, Claude Bachmeyer, Sarah Guégan
is missing (Short communication).
October 10, 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/27686963/safety-profile-of-biologic-drugs-in-the-therapy-of-crohn-disease-a-systematic-review-and-network-meta-analysis
#3
Paweł Moćko, Paweł Kawalec, Andrzej Pilc
BACKGROUND: Crohn disease (CD) is an inflammatory bowel disease which occurs especially in developed countries of Western Europe and North America. The aim of the study was to compare the safety profile of biologic drugs in patients with CD. METHODOLOGY: A systematic literature search was performed using PubMed, Embase, and CENTRAL databases, until April 27, 2016. We included randomized controlled trials (RCTs) that compared the safety of biologic drugs (infliximab, adalimumab, vedolizumab, certolizumab pegol, and ustekinumab) with one another or with placebo in patients with CD...
August 1, 2016: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/27450626/ustekinumab-for-the-treatment-of-crohn-s-disease
#4
Tawnya Hansen, Laura E Targownik
INTRODUCTION: Ustekinumab is a human monoclonal antibody directed against the shared p40 subunit of interleukins 12 and 23. Ustekinumab is currently approved for the treatment of psoriatic arthritis (PsA) and moderate to severe plaque psoriasis, and is being evaluated in Crohn's disease (CD). AREAS COVERED: The first evidence supporting the efficacy of ustekinumab in the treatment of moderate to severe CD was published in 2008. Results from subsequent phase II and phase III randomized controlled trials (RCTs) have shown promising data on the clinical efficacy of induction and remission of moderate to severe CD...
September 2016: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27433311/ustekinumab-in-crohn-s-disease-evidence-to-date-and-place-in-therapy
#5
REVIEW
Tal Engel, Uri Kopylov
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending...
July 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27341173/ustekinumab-a-novel-therapeutic-option-in-crohn-s-disease
#6
E G Simon, S Samuel, S Ghosh, G W Moran
INTRODUCTION: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23. AREAS COVERED: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world...
August 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27306074/the-next-wave-of-biological-agents-for-the-treatment-of-ibd-evidence-from-cochrane-reviews
#7
Reena Khanna, Nilesh Chande, Séverine Vermeire, William J Sandborn, Claire E Parker, Brian G Feagan
Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session...
July 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27306072/ustekinumab-for-the-treatment-of-refractory-crohn-s-disease-the-spanish-experience-in-a-large-multicentre-open-label-cohort
#8
Sam Khorrami, Daniel Ginard, Ignacio Marín-Jiménez, María Chaparro, Mónica Sierra, Mariam Aguas, Beatriz Sicilia, Valle García-Sánchez, Cristina Suarez, Albert Villoria, Carlos Taxonera, Antonio Velasco-Guardado, Javier Martínez-González, Javier P Gisbert
BACKGROUND: Ustekinumab is a fully human monoclonal antibody against IL-12/23. Ustekinumab induced clinical response and maintained higher rate of response than placebo in patients with Crohn's disease (CD). This study aims to assess the effectiveness and safety of ustekinumab in refractory patients with CD in real-life practice. METHODS: Consecutive patients with CD who were treated with subcutaneous ustekinumab between March 2010 and December 2014 were retrospectively included in a multicenter open-label study...
July 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27231440/a-special-meeting-review-edition-ccfa-advances-in-inflammatory-bowel-diseases-2015-highlights-in-ulcerative-colitis-and-crohn-s-disease-a-review-of-selected-presentations-from-the-ccfa-advances-in-inflammatory-bowel-diseases-2015-clinical-and-research-conference
#9
https://www.readbyqxmd.com/read/26958561/ustekinumab-for-successful-treatment-of-refractory-esophageal-crohn-s-disease
#10
Jodie A Barkin, Amar R Deshpande
Esophageal involvement in Crohn's disease is rare. We present a case of refractory esophageal Crohn's disease that responded to ustekinumab, which has shown promise in the treatment of refractory, typically intestinal Crohn's disease. There are no prior reports on the successful use of ustekinumab in esophageal Crohn's disease, but should be considered as a possible management strategy in patients with this condition.
January 2016: ACG Case Reports Journal
https://www.readbyqxmd.com/read/26910458/ustekinumab-in-treatment-of-refractory-paediatric-crohn-disease
#11
LETTER
F L Cameron, V Garrick, R K Russell
No abstract text is available yet for this article.
March 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/26854655/ustekinumab-in-pediatric-crohn-disease-patients
#12
Casey Bishop, Hayley Simon, David Suskind, Dale Lee, Ghassan Wahbeh
OBJECTIVES: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center. METHODS: A retrospective chart review was done to identify patients' clinical data, disease phenotype, treatment history, and laboratory and growth parameters before treatment with ustekinumab and at last follow-up. Adverse events while on ustekinumab were also recorded. RESULTS: Four adolescent patients with Crohn disease at our center received ustekinumab...
September 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/26849718/o-001%C3%A2-a-multicenter-double-blind-placebo-controlled-phase3-study-of-ustekinumab-a-human-il-12-23p40-mab-in-moderate-service-crohn-s-disease-refractory-to-anti-tfn%C3%AE-uniti-1
#13
William Sandborn, Christopher Gasink, Marion Blank, Yinghua Lang, Jewel Johanns, Long-Long Gao, Bruce Sands, Stephen Hanauer, Brian Feagan, Stephan Targan, Subrata Ghosh, Wim de Villiers, Jean-Frédéric Colombel, Scott Lee, Pierre Desreumaux, Edward Loftus, Severine Vermeire, Paul Rutgeerts
BACKGROUND: Interleukins 12&23 are implicated in the pathophysiology of Crohn's disease (CD). These pro-inflammatory cytokines are blocked by ustekinumab (UST). In a previous Phase 2b study (CERTIFI), UST IV induction followed by SC maintenance was shown effective in moderate-severe CD refractory to anti-TNF therapy. This Phase 3 study examined the efficacy and safety of IV UST induction in these patients. METHODS: Patients with moderate-severely active CD (CDAI 220-450) who previously failed or were intolerant to at least 1 TNF-antagonist were randomized (1:1:1) at Week (Wk) 0 to a single dose of IV placebo (PBO), UST 130 mg, or weight-based tiered UST dosing approximating 6 mg/kg (260mg [weight ≤55 kg], 390mg [weight >55 kg and ≤85 kg], 520mg [weight >85 kg])...
March 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/26839964/emerging-issues-in-the-medical-management-of-crohn-s-disease
#14
Laura E Targownik, J Gerard Coneys, Amit S Dhillon
PURPOSE OF REVIEW: This article describes why this review is timely and relevant. The medical management of Crohn's disease is complex, and is changing rapidly with the introduction of novel therapeutic agents and management strategies. RECENT FINDINGS: We have summarized and synthesized up-to-date evidence and opinion on the proper role and composition of combined immunosuppressive therapy in the management of Crohn's disease, the optimal time for introduction of immunomodulator and/or biologic therapies, and the benefits of therapeutic drug monitoring for biologic therapies...
March 2016: Current Opinion in Gastroenterology
https://www.readbyqxmd.com/read/26836588/variants-in-trim22-that-affect-nod2-signaling-are-associated-with-very-early-onset-inflammatory-bowel-disease
#15
Qi Li, Cheng Hiang Lee, Lauren A Peters, Lucas A Mastropaolo, Cornelia Thoeni, Abdul Elkadri, Tobias Schwerd, Jun Zhu, Bin Zhang, Yongzhong Zhao, Ke Hao, Antonio Dinarzo, Gabriel Hoffman, Brian A Kidd, Ryan Murchie, Ziad Al Adham, Conghui Guo, Daniel Kotlarz, Ernest Cutz, Thomas D Walters, Dror S Shouval, Mark Curran, Radu Dobrin, Carrie Brodmerkel, Scott B Snapper, Christoph Klein, John H Brumell, Mingjing Hu, Ralph Nanan, Brigitte Snanter-Nanan, Melanie Wong, Francoise Le Deist, Elie Haddad, Chaim M Roifman, Colette Deslandres, Anne M Griffiths, Kevin J Gaskin, Holm H Uhlig, Eric E Schadt, Aleixo M Muise
BACKGROUND & AIMS: Severe forms of inflammatory bowel disease (IBD) that develop in very young children can be caused by variants in a single gene. We performed whole-exome sequence (WES) analysis to identify genetic factors that might cause granulomatous colitis and severe perianal disease, with recurrent bacterial and viral infections, in an infant of consanguineous parents. METHODS: We performed targeted WES analysis of DNA collected from the patient and her parents...
May 2016: Gastroenterology
https://www.readbyqxmd.com/read/26770265/ustekinumab-for-the-treatment-of-crohn-s-disease-can-it-find-its-niche
#16
REVIEW
Ebby G Simon, Subrata Ghosh, Marietta Iacucci, Gordon W Moran
Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option...
January 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/26535119/biologics-in-inflammatory-bowel-disease-what-are-the-data
#17
REVIEW
Justin Côté-Daigneault, Mickael Bouin, Raymond Lahaie, Jean-Frédéric Colombel, Pierre Poitras
BACKGROUND: Over the last decade, biologics have gained an important place for the treatment of moderate to severe inflammatory bowel disease (IBD), and many randomized control trials have evaluated their efficacy. AIM: The goal of this review is to analyze the results of these trials and to highlight the evidence and indications emerging from these studies for their implementation in the management of IBD patients. METHODS: A PubMed search was realized to screen high-quality clinical trials studying biologic agents currently available in clinics for the treatment of IBD...
October 2015: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/26520192/-treatment-of-inflammatory-bowel-diseases
#18
Fernando Gomollón
In addition to immunosuppressive drugs and anti-TNF, there are a number of new options in the treatment of inflammatory bowel diseases. Vedolizumab has been approved by the FDA and EMA and has demonstrated utility both in the treatment of ulcerative colitis (UC) and Crohn's disease (CD), even in anti-TNF refractory patients. Other monoclonal antibodies with different targets such as PF-005447659 (antiMAd-CAM1), ustekinumab (anti-IL23/IL12) or MEDI2070 (anti-IL23) have shown promising results in distinct clinical scenarios...
September 2015: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/26368546/observational-case-series-on-adalimumab-induced-paradoxical-hidradenitis-suppurativa
#19
Marine Delobeau, Ahlam Abdou, Eve Puzenat, Elise Deveza, Caroline Biver-Dalle, Alison van de Laak, Blandine Roche-Kubler, Lucine Vuitton, Stéphane Koch, Daniel Wendling, François Aubin
INTRODUCTION: Although the efficacy of TNF blockers has been demonstrated in hidradenitis suppurativa (HS), many paradoxical effects have also been described with TNF antagonists. We wished to describe patients with adalimumab (ADA)-induced paradoxical HS. METHODS: This is a retrospective descriptive case series of four patients with ADA-induced paradoxical HS. RESULTS: All the patients had a good response to TNFa antagonist therapy at the time of HS occurrence...
2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/26366705/the-il-12-23-stat-axis-as-a-therapeutic-target-in-inflammatory-bowel-disease-mechanisms-and-evidence-in-man
#20
Irene Marafini, Erika Angelucci, Francesco Pallone, Giovanni Monteleone
BACKGROUND: In inflamed tissues of patients with inflammatory bowel disease (IBD), many immune and non-immune cells produce a vast array of cytokines, which contribute to expand and maintain the pathologic process. Key Message: Interleukin (IL)-12 and IL-23, 2 heterodimeric cytokines sharing the common p40 subunit, are over-produced in IBD and supposed to play a major role in promoting and/or sustaining the pro-inflammatory cytokine response in these disorders. IL-12 targets mostly T cells and innate lymphoid cells and through activation of Stat4 promotes T helper (Th)1 cell polarization, interferon-x03B3; and IL-21 production, while IL-23 activates Stat3 thus amplifying Th17 cell programs...
September 14, 2015: Digestive Diseases
keyword
keyword
44834
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"